Clinical Trial

Clinical Trial of PCV24 in Infants Aged 2-23 Months

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase Ib clinical trial.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-28; most recent amendment 2026-01-26.
Status change: Not Yet Recruiting → Recruiting 2026-01-26
Trial Details
NCT Number NCT06800261
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions Pneumococcal Infectious Disease
Enrollment 180 participants
Start Date 2025-05-08
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-28